Search

Your search keyword '"Liggett W"' showing total 112 results

Search Constraints

Start Over You searched for: Author "Liggett W" Remove constraint Author: "Liggett W"
112 results on '"Liggett W"'

Search Results

6. Abstract P4-22-09: A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer

8. P3-14-29: Neoadjuvant Sunitinib Administered with Weekly Paclitaxel/Carboplatin in Patients with Locally Advanced Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.

11. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network

12. Topotecan—Single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): A Minnie Pearl Cancer Research Network phase II trial

14. Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Research Network phase II trial

15. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network

27. Interlaboratory comparison of actinides in human tissue239Pu and240Pu

28. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group.

31. Covariance of Noise in Attenuating Media.

32. Passive Sonar Processing for Noise with Unknown Covariance Structure.

33. Noise Covariance and Vertical Directivity in a Deep Ocean.

34. Covariance of Surface-Generated Noise in a Deep Ocean.

35. Interlaboratory comparison of actinides in human tissue239Pu and240Pu

36. Albumin-eicosanoid interactions. A model system to determine their attributes and inhibition.

37. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry.

38. Metabolism of leukotriene A4 by human erythrocytes. A novel cellular source of leukotriene B4.

40. Development of the Automated Dynamic Model for the Integrated Facilities Requirements Study (IFRS). Volume III. Dynamic Model Programmer's Manual.

41. Development of the Optimization Model for the Integrated Facilities Requirements Study (IFRS) Phase III. Volume II. Formulation and Use of the IFRS Optimization Model.

42. The Integrated Facilities Requirements Study (IFRS) Phase III. Volume II. Phase III Changes to User's and Programmer's Manuals.

43. Development of the Optimization Model for the Integrated Facilities Requirements Study (IFRS) Phase III. Volume I. Summary of the Optimization Model.

44. Development of the Automated Dynamic Model for the Integrated Facilities Requirements Study (IFRS). Volume II. Dynamic Model User's Manual.

45. Development of the Fleet Air Readiness Training Model for the Integrated Facilities Requirements Study (IFRS) Phase III. Volume I. Summary of the Fleet Readiness Training (FRT) Management Planning Tool.

46. Development of the Automated Dynamic Model for the Integrated Facilities Requirements Study (IFRS). Volume I. Summary of the Dynamic Management Planning Tool.

47. Development of the Fleet Air Readiness Training Model for the Integrated Facilities Requirements Study (IFRS Phase III. Volume III. FRT User's Manual.

48. Development of the Fleet Air Readiness Training Model for the Integrated Facilities Requirements Study (IFRS) Phase III. Volume IV. FRT Programmer's Manual Readiness Training (FRT) Management Planning Tool.

49. The Integrated Facilities Requirements Study (IFRS) Phase III. Volume I. Summary.

Catalog

Books, media, physical & digital resources